Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adenovirus-mediated gene therapy in a mouse model of glycogen storage disease type 1a.

European journal of pediatrics - 1 Oct 2002

Chou Janice Yang, Zingone Adriana, Pan Chi-Jiunn

Abstract excerpt

UNLABELLED: Glycogen storage disease type 1a (GSD-1a), characterized by growth retardation, hypoglycemia, hepatomegaly, kidney enlargement, hyperlipidemia, hyperuricemia, and renal dysfunction, is caused by deficiencies in glucose-6-phosphatase (G6Pase), a key enzyme in glucose homeostasis. Over the last 20 years, dietary therapies have greatly improved the prognosis of GSD-1a patients. However, the underlying...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoviridae
Share to Disease Models, Animal
Share to Genetic Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Vectors

Share to Glucose-6-Phosphatase

Share to Glycogen Storage Disease Type I

Share to Mice, Knockout

Source

Identifiers

PMID: 12373573
DOI: 10.1007/s00431-002-1005-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adenovirus-mediated gene therapy in a mouse model of glycogen storage disease type 1a.PMID 12373573Read ↗

Gene therapy for glycogen storage diseasesSemantic proximity Read ↗

Molecular biology and gene therapy for glycogen storage disease type Ib.Semantic proximity Read ↗

Gene therapy for glycogen storage diseasesSemantic proximity Read ↗

Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model.Semantic proximity Read ↗

Rescue of GSDIII Phenotype with Gene Transfer Requires Liver- and Muscle-Targeted GDE Expression.Semantic proximity Read ↗

Gene therapy and genome editing for type I glycogen storage diseasesSemantic proximity Read ↗

Long‐term safety and efficacy of AAV gene therapy in the canine model of glycogen storage disease type IaSemantic proximity Read ↗

Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-α-glucosidaseSemantic proximity Read ↗

Long-term correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transferSemantic proximity Read ↗

Gene therapy for urea cycle defects: An update from historical perspectives to future prospectsSemantic proximity Read ↗

A splice-switching oligonucleotide treatment ameliorates glycogen storage disease type 1a in mice with G6PC c.648G>TSemantic proximity Read ↗

Glucose-6-phosphatase dependent substrate transport in the glycogen storage disease type-1a mouse.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.